Advocating the potential for a single dose of #SARSCoV2 vaccines @zeynep @michaelmina_lab https://www.nytimes.com/2020/12/18/opinion/coronavirus-vaccine-doses.html?action=click&module=Opinion&pgtype=Homepage …
The points for studying this are good but the public message to many for skipping the 2nd dose is troubling when we don't really know what protection that provides
-
-
Let's say we run the trial and 80-90% holds up and have 50 million doses allocated to younger, essential workers. The question would be vaccinate 25 million (25 million get 95% but 25 million get 0% efficacy) versus 50 million with 80-90%. Trade-off either way, given shortage.
-
How fast would we need to get the trial done?
- Show replies
New conversation -
-
-
Peter Marks/FDA said Mon that concern w/1 dose could also be that immune response dwindles faster. "And we know that can happen because we know already that people who get very mild covid-19 tend to lose their immune responses pretty quickly." 6 min markhttps://www.youtube.com/watch?v=uePet5k9wMo …
-
Yes, and additionally that’s a concern for the booster as well. Hence the need for a trial, and proper follow up even for people who got the booster. We don’t really have long-term data on either at the moment.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.